查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573713

衣原體感染診斷市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Chlamydia Infection Diagnostics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 100 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球衣原體感染診斷市場估值為 15 億美元。

即時檢測 (POC) 檢測對於檢測沙眼衣原體至關重要，具有高靈敏度和特異性。向分子診斷的轉變強調了對準確、及時的感染識別、減少併發症和傳播風險的需求。

由於患者對便利性和隱私的偏好，家庭檢測套件呈上升趨勢。多重檢測等創新技術能夠同時檢測多種性傳染感染 (STI)，因其效率和成本效益而變得越來越受歡迎。公共衛生運動和教育措施提高了意識並促進定期檢查，進一步推動市場成長。

政府措施也促進了市場擴張。例如，2021 年 6 月，英國政府在其國家衣原體篩檢計畫 (NCSP) 中重點關注女性，並認知到她們發生嚴重感染結果的風險較高。此舉旨在為 25 歲以下性活躍的女性提供快速治療並擴大社區檢測。

整個衣原體感染診斷產業根據測試類型、感染類型、最終用途和地區進行分類。

2023 年，核酸擴增測試 (NAAT) 領域憑藉其無與倫比的靈敏度和特異性引領市場，產生約 6.683 億美元的收入。它們能夠檢測最低限度的沙眼衣原體 DNA 水平，確保準確的感染識別。這種準確性減少了誤報，保證了更可靠的診斷。鑑於許多衣原體感染，尤其是女性衣原體感染，是無症狀的，NAAT 確定這些病例的能力對於早期干預、預防骨盆腔炎和不孕症等併發症至關重要。 NAAT 通常在數小時內即可提供快速結果，這對於及時診斷和治療至關重要。這種速度增強了患者管理並減少了感染傳播。

2023 年，醫院將成為市場的主導部分，預計在預測期內將實現 7.4% 的強勁成長率。醫院配備了尖端的診斷技術和實驗室，可以進行各種測試，包括 NAAT 和其他分子診斷。這種全面的基礎設施使醫院能夠提供精確、高效的衣原體檢測，鞏固其市場主導地位。由於患者流動率很高，包括那些有性傳染感染症狀或進行常規篩檢的患者，醫院強大的診斷能力使他們成為衣原體診斷的主要使用者。提供全方位方法（診斷、治療和隨訪）的醫院可提高患者的便利性並確保護理的連續性，使其成為衣原體檢測的首選場所。

2023年，北美衣原體感染診斷市場收入為5.881億美元，預計未來幾年將大幅成長。尤其是美國，它是世界上衣原體感染率最高的國家之一，這刺激了對有效診斷解決方案的需求。疾病預防控制中心等組織倡導定期篩檢和早期衣原體檢測。他們的舉措，從針對 25 歲以下人群的常規篩檢到針對高風險族群的針對性計劃，擴大了對診斷測試的需求。在強調性傳染感染檢測和現代診斷工具重要性的宣傳活動的推動下，人們對性傳染感染及其健康影響的認知和教育不斷提高，正在提高檢測率並推動市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 披衣菌感染盛行率上升
      • 診斷技術的進步
      • 擴大採用家庭檢測套件
      • 政府措施和資金的增加
    • 產業陷阱與挑戰
      • 低收入和中等收入國家缺乏認知
      • 社會恥辱與保密問題
  • 成長潛力分析
  • 監管環境
  • 未來市場趨勢
  • 技術景觀
  • 波特的分析
  • PESTEL分析
  • 差距分析
  • 產品管道分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

  • 主要趨勢
  • 核酸擴增檢驗（NAAT）
  • 血清學檢測
  • 直接螢光抗體檢測
  • 文化測試
  • 其他測試類型

第 6 章：市場估計與預測：按感染類型，2021 - 2032 年

  • 主要趨勢
  • 生殖器衣原體感染
  • 直腸披衣菌感染
  • 眼衣原體感染

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 專科診所
  • 診斷中心

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Abbott
  • BD
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • QuidelOrtho Corporation.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech Plc.
簡介目錄
Product Code: 11042

The Global Chlamydia Infection Diagnostics Market was valued at USD 1.5 billion in 2023. Projections indicate a growth trajectory, with an anticipated CAGR of 7.1% from 2024 to 2032, driven by technological advancements, heightened awareness, and shifting healthcare demands.

Point-of-care (POC) tests are pivotal in detecting Chlamydia trachomatis, boasting high sensitivity and specificity. The shift towards molecular diagnostics underscores the demand for precise and timely infection identification, reducing complications and transmission risks.

There's a rising trend in home-based testing kits due to patients' preference for convenience and privacy. Innovations like multiplex assays, which enable simultaneous detection of multiple sexually transmitted infections (STIs), are becoming popular for their efficiency and cost-effectiveness. Public health campaigns and educational initiatives boost awareness and promote regular screenings, further propelling market growth.

Government initiatives also bolster market expansion. For instance, in June 2021, the U.K. government spotlighted women in its National Chlamydia Screening Programme (NCSP), recognizing their heightened risk of severe infection outcomes. This move aims to fast-track treatment and expand community testing for sexually active women under 25.

The overall Chlamydia infection diagnostics industry is classified based on test type, type of infections, end-use, and region.

In 2023, the nucleic acid amplification test (NAAT) segment led the market, generating approximately USD 668.3 million in revenues, owing to their unmatched sensitivity and specificity. Their capability to detect minimal Chlamydia trachomatis DNA levels ensures accurate infection identification. This accuracy diminishes false negatives, guaranteeing more dependable diagnoses. Given that many chlamydia infections, especially in women, are asymptomatic, NAATs' ability to pinpoint these cases is vital for early intervention, preventing complications like pelvic inflammatory disease and infertility. NAATs deliver swift results, often within hours, crucial for prompt diagnosis and treatment. This rapidity enhances patient management and curtails infection spread.

In 2023, hospitals emerged as the dominant segment in the market, with projections indicating a robust growth rate of 7.4% during the forecast period. Equipped with cutting-edge diagnostic technologies and laboratories, hospitals can conduct a diverse array of tests, including NAATs and other molecular diagnostics. This comprehensive infrastructure empowers hospitals to deliver precise and efficient chlamydia testing, solidifying their market prominence. With a high patient turnover, including those with STI symptoms or routine screenings, hospitals' robust diagnostic capabilities position them as primary users of chlamydia diagnostics. Offering an all-encompassing approach-diagnosis, treatment, and follow-up-hospitals enhance patient convenience and ensure care continuity, making them the preferred venue for chlamydia testing.

In 2023, North America accounted for a revenue of USD 588.1 million in the chlamydia infection diagnostics market, with expectations of significant growth in the coming years. The U.S., in particular, grapples with one of the world's highest chlamydia infection rates, spurring a demand for effective diagnostic solutions. Organizations like the CDC champion regular screenings and early chlamydia detection. Their initiatives, from routine screenings for those under 25 to targeted programs for high-risk groups, amplify the demand for diagnostic tests. Heightened awareness and education surrounding STIs and their health ramifications, bolstered by campaigns emphasizing the significance of STI testing and modern diagnostic tools, are driving up testing rates and fueling market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chlamydia infections
      • 3.2.1.2 Advancements in diagnostic technologies
      • 3.2.1.3 Growing adoption of home testing kits
      • 3.2.1.4 Increase in government initiatives and funding
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Lack of awareness in low and middle-income countries
      • 3.2.2.2 Social stigma and confidentiality concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Technological landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Gap analysis
  • 3.10 Product pipeline analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2023
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Nucleic acid amplification test (NAAT)
  • 5.3 Serology test
  • 5.4 Direct fluorescent antibody test
  • 5.5 Culture test
  • 5.6 Other test types

Chapter 6 Market Estimates and Forecast, By Type of Infections, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Genital chlamydia infection
  • 6.3 Rectal chlamydia infection
  • 6.4 Ocular chlamydia infection

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Diagnostic centres

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 BD
  • 9.3 Bio-Rad Laboratories, Inc.
  • 9.4 DiaSorin S.p.A.
  • 9.5 F. Hoffmann-La Roche Ltd
  • 9.6 Hologic, Inc.
  • 9.7 QuidelOrtho Corporation.
  • 9.8 Siemens Healthineers
  • 9.9 Thermo Fisher Scientific Inc.
  • 9.10 Trinity Biotech Plc.